{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:44:28Z","timestamp":1777866268114,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020366","name":"Massachusetts Consortium on Pathogen Readiness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020366","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA260476"],"award-info":[{"award-number":["CA260476"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI69309"],"award-info":[{"award-number":["AI69309"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.vaccine.2024.126306","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T06:36:44Z","timestamp":1725518204000},"page":"126306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Insights from an observational translational research program during the COVID-19 pandemic: Four years of experience"],"prefix":"10.1016","volume":"42","author":[{"given":"Marjorie","family":"Rowe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai-ris Yonekura","family":"Collier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan H.","family":"Barouch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.126306_bb0010","author":"News ABC"},{"issue":"7","key":"10.1016\/j.vaccine.2024.126306_bb0015","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s41374-022-00743-5","article-title":"QuantISH: RNA in situ hybridization image analysis framework for quantifying cell type-specific target RNA expression and variability","volume":"102","author":"Jamalzadeh","year":"2022","journal-title":"Lab Investig"},{"issue":"12","key":"10.1016\/j.vaccine.2024.126306_bb0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.30455","article-title":"Assessment of maternal and neonatal SARS-CoV-2 viral load, Transplacental antibody transfer, and placental pathology in pregnancies during the COVID-19 pandemic","volume":"3","author":"Edlow","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"14","key":"10.1016\/j.vaccine.2024.126306_bb0030","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00404-21","article-title":"Correlates of neutralization against SARS-CoV-2 variants of concern by early pandemic sera","volume":"95","author":"Vidal","year":"2021","journal-title":"J Virol"},{"issue":"23","key":"10.1016\/j.vaccine.2024.126306_bb0035","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.2021.7563","article-title":"Immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women","volume":"325","author":"Collier A ris","year":"2021","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.vaccine.2024.126306_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajogmf.2021.100386","article-title":"Vertical transmission of SARS-CoV-2: consider the denominator","volume":"3","author":"Shook","year":"2021","journal-title":"Am J Obstet Gynecol MFM"},{"issue":"7","key":"10.1016\/j.vaccine.2024.126306_bb0045","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/infdis\/jiab569","article-title":"Coronavirus disease 2019 messenger RNA vaccine immunogenicity in immunosuppressed individuals","volume":"225","author":"Collier A ris","year":"2021","journal-title":"J Infect Dis"},{"issue":"641","key":"10.1016\/j.vaccine.2024.126306_bb0050","article-title":"Characterization of immune responses in fully vaccinated individuals after breakthrough infection with the SARS-CoV-2 delta variant","volume":"14","author":"Collier Aris","year":"2022","journal-title":"Sci Transl Med"},{"issue":"21","key":"10.1016\/j.vaccine.2024.126306_bb0055","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMc2115596","article-title":"Differential kinetics of immune responses elicited by Covid-19 vaccines","volume":"385","author":"Collier","year":"2021","journal-title":"N Engl J Med"},{"issue":"7901","key":"10.1016\/j.vaccine.2024.126306_bb0060","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-022-04465-y","article-title":"Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 omicron","volume":"603","author":"Liu","year":"2022","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.vaccine.2024.126306_bb0065","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMc2201849","article-title":"Neutralization of the SARS-CoV-2 omicron BA.1 and BA.2 variants","volume":"386","author":"Jingyou","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126306_bb0070","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJMc2206576","article-title":"Neutralization escape by SARS-CoV-2 omicron subvariants BA.2.12.1, BA.4, and BA.5","volume":"387","author":"Hachmann","year":"2022","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.vaccine.2024.126306_bb0075","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1056\/NEJMc2212117","article-title":"Neutralization escape by SARS-CoV-2 omicron subvariant BA.4.6","volume":"387","author":"Hachmann","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.vaccine.2024.126306_bb0080","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1056\/NEJMc2214314","article-title":"Substantial neutralization escape by SARS-CoV-2 omicron variants BQ.1.1 and XBB.1","volume":"388","author":"Jessica","year":"2023","journal-title":"N Engl J Med"},{"issue":"47","key":"10.1016\/j.vaccine.2024.126306_bb0085","doi-asserted-by":"crossref","first-page":"6904","DOI":"10.1016\/j.vaccine.2023.10.051","article-title":"Neutralization escape by SARS-CoV-2 omicron subvariant BA.2.86","volume":"41","author":"Lasrado","year":"2023","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2024.126306_bb0090","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.vaccine.2024.03.007","article-title":"Neutralization of SARS-CoV-2 omicron subvariant BA.2.87.1","volume":"42","author":"Lasrado","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126306_bb0095","author":"CDC"},{"key":"10.1016\/j.vaccine.2024.126306_bb0110","series-title":"Types and Uses of Biorepositories and Their Application to Registries. In: Biorepositories: Addendum to Registries for Evaluating Patient Outcomes: A User\u2019s Guide","author":"Greenberg","year":"2018"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126306_bb0115","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.cell.2021.12.027","article-title":"Transmission from vaccinated individuals in a large SARS-CoV-2 Delta variant outbreak","volume":"185","author":"Siddle","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2024.126306_bb0120","article-title":"Coronavirus pandemic (COVID-19)","volume":"5","author":"Mathieu","year":"2020","journal-title":"Our World Data Published online March"},{"issue":"6","key":"10.1016\/j.vaccine.2024.126306_bb0125","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1056\/NEJMc2213948","article-title":"Immunogenicity of BA.5 bivalent mRNA vaccine boosters","volume":"388","author":"Collier","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.126306_bb0130","unstructured":"LaFraniere S, Weiland N. F.D.A. to authorize Third vaccine dose for people with weak immune systems. The New York Times. https:\/\/www.nytimes.com\/2021\/08\/11\/us\/politics\/third-vaccine-dose-approval.html. Published August 12, 2021. Accessed May 7, 2024."},{"key":"10.1016\/j.vaccine.2024.126306_bb0135","unstructured":"Mueller B. Another covid surge may be coming. are we ready for it? The New York Times https:\/\/wwwnytimescom\/2022\/03\/19\/health\/covid-ba2-surge-varianthtml, Published March 19, 20222022. [Accessed May 7, 2024]."},{"key":"10.1016\/j.vaccine.2024.126306_bb0140","unstructured":"Smith DG. Who should get a covid booster now? new data offers some clarity. The New York Times. https:\/\/www.nytimes.com\/2023\/02\/02\/well\/live\/covid-bivalent-booster-omicron.html. Published February 2, 2023. Accessed May 7, 2024."},{"key":"10.1016\/j.vaccine.2024.126306_bb0150","author":"News ABC"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24009885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24009885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:20:33Z","timestamp":1777537233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24009885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":25,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0264410X24009885"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126306","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insights from an observational translational research program during the COVID-19 pandemic: Four years of experience","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126306","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126306"}}